News

10/07/2025

«Generium-Next» plant was officialy opened in Alabushevo

A new pharmaceutical plant «Generium-Next» was officially opened in the Alabushevo site of the special economic zone "Technopolis Moscow". The facility is dedicated to manufacturing vital and socially significant drugs.

«Generium-Next» plant was officialy opened in Alabushevo

08/13/2025

Russia’s ministry of health registers first Russian biosimilar of aflibercept, produced by GENERIUM

The Ministry of Health of the Russian Federation has issued a marketing authorization to GENERIUM for Continia® (Registration Certificate №11113-(РГ-RU), the first Russian-developed biosimilar of aflibercept. The drug is indicated for the treatment of ophthalmological diseases in patients aged 18 and older.

05/26/2025

GENERIUM Registers Biosimilar of Tenecteplase for Acute Myocardial Infarction and Ischemic Stroke Treatment

The Russian Ministry of Health has issued a marketing authorization to GENERIUM for Nekteliza® (INN: tenecteplase), a fibrinolytic agent. The approved indications for this biosimilar include thrombolytic therapy for acute myocardial infarction and ischemic stroke in adults.

03/06/2025

GENERIUM initiates clinical trial of original gene therapy drug for Duchenne muscular dystrophy treatment

GENERIUM has received approval to conduct a clinical trial of a gene therapy drug for the treatment of progressive Duchenne muscular dystrophy (DMD).

03/03/2025

Ministry of Health of Russia has registered the first biosimilar of ustekinumab – GENERIUM’s drug for the treatment of autoimmune rheumatological diseases

GENERIUM has received marketing authorization1 for its drug "Styleikin"® (INN: ustekinumab), intended for the treatment of plaque psoriasis and psoriatic arthritis in children and adults.

02/20/2025

Izvestia. Local news Overcoming mistrust: SMA patients in Russia have started to receive a domestic drug

How the Russian pharma industry overcomes patient mistrust

01/13/2025

GENERIUM has registered the first domestic device for analyzing tuberculosis test results.

GENERIUM has received a registration certificate for the medical device "SCREENSPOT" - a microplate analyzer for automated reading and analysis of tuberculosis test results based on the ELISPOT method. The equipment is intended for clinical diagnostic laboratories and is capable of enhancing their operational efficiency.

09/25/2024

The Ministry of Health of the Russian Federation has registered the first biosimilar of tocilizumab - a drug from the company GENERIUM.

01/19/2024

GENERIUM – the first in Russia to receive a registration certificate for a biomedical cell product

The first advanced therapy medicinal product (ATMP) in Russia was registered by GENERIUM under the trade name EASYTENSE. It is an autologous product based on chondrocytes, the main cells of cartilage tissue, and is intended for the restoration of damage to the cartilage of the knee joint with a defect area of up to 10 square cm.

12/07/2023

GENERIUM has registered a biosimilar of ranibizumab, a medicine for treatment of age-related macular degeneration

The medicine from GENERIUM under the trade name Laxolan® received a registration certificate from the Ministry of Health. It is intended to treat age-related macular degeneration, as well as certain other retinal diseases that are a common cause of vision loss.